Rocket


News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
AMARIN CORP PLC (AMRN) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/29/2021 GN Amarin Reports First Quarter 2021 Financial Results and Provides Business Update
04/29/2021 GN Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel
04/22/2021 GN Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2
04/20/2021 GN Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021
04/17/2021 GN VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021
04/06/2021 GN Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication
03/17/2021 GN VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Conference 2021
02/25/2021 GN Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
02/18/2021 GN Amarin to Present at Two Upcoming Investor Conferences
02/17/2021 GN Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021
02/16/2021 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2021 GN Amarin Provides Update on VASCEPA® (Icosapent Ethyl) Regulatory Review Processes in Mainland China and Hong Kong
01/29/2021 GN Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction
01/25/2021 GN Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit to Include Health Care Insurance Provider
01/21/2021 GN Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases
01/07/2021 GN Amarin Provides Preliminary 2020 Results and 2021 Outlook
01/04/2021 GN Amarin to Present at 39th Annual J.P. Morgan Healthcare Conference
12/14/2020 GN Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results
12/12/2020 GN Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020
12/07/2020 GN VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessions 2020
11/30/2020 GN Amarin Files Patent Infringement Lawsuit Against Hikma
11/24/2020 GN Amarin to Present at Piper Sandler's 32nd Annual Healthcare Conference (Virtual)
11/19/2020 GN Amarin Shares Topline Data from Partner's Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China
11/13/2020 GN VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting (CABG) Procedures in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association's Virtual Scientific Sessions 2020
11/11/2020 GN Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences
11/05/2020 GN Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update
10/26/2020 GN VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Cardiovascular Events in Patients with Compromised Renal Function at Baseline in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Society of Nephrology (ASN) Kidney Week 2020
10/23/2020 GN U.S. Veterans with Decreased Renal Function Shown to Be at Higher Risk for Adverse Cardiovascular Events if They Have Moderately Elevated Triglyceride (TG) Levels Despite Well-Controlled Low-Density Lipoprotein (LDL)-Cholesterol
10/19/2020 GN Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020
10/15/2020 GN VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Intervention (PCI) in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at Transcatheter Cardiovascular Therapeutics (TCT) Connect 2020
10/05/2020 GN Latest Research Evaluating VASCEPA® (Icosapent Ethyl) Mechanisms of Action Presented at European Atherosclerosis Society (EAS) Congress 2020
09/03/2020 GN Amarin Provides Update Following Ruling in VASCEPA® ANDA Patent Litigation
09/01/2020 GN Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Risk Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology
08/29/2020 GN VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy